Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Depreciation & Amortization (CF) (2017 - 2025)

Historic Depreciation & Amortization (CF) for Protagonist Therapeutics (PTGX) over the last 9 years, with Q3 2025 value amounting to $361000.0.

  • Protagonist Therapeutics' Depreciation & Amortization (CF) rose 5627.71% to $361000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 million, marking a year-over-year increase of 690.38%. This contributed to the annual value of $826000.0 for FY2024, which is 1545.55% down from last year.
  • According to the latest figures from Q3 2025, Protagonist Therapeutics' Depreciation & Amortization (CF) is $361000.0, which was up 5627.71% from $304000.0 recorded in Q2 2025.
  • Over the past 5 years, Protagonist Therapeutics' Depreciation & Amortization (CF) peaked at $361000.0 during Q3 2025, and registered a low of $118000.0 during Q4 2024.
  • Its 5-year average for Depreciation & Amortization (CF) is $239684.2, with a median of $241000.0 in 2024.
  • In the last 5 years, Protagonist Therapeutics' Depreciation & Amortization (CF) plummeted by 5241.94% in 2024 and then surged by 5627.71% in 2025.
  • Over the past 5 years, Protagonist Therapeutics' Depreciation & Amortization (CF) (Quarter) stood at $235000.0 in 2021, then rose by 8.94% to $256000.0 in 2022, then fell by 3.12% to $248000.0 in 2023, then tumbled by 52.42% to $118000.0 in 2024, then soared by 205.93% to $361000.0 in 2025.
  • Its Depreciation & Amortization (CF) was $361000.0 in Q3 2025, compared to $304000.0 in Q2 2025 and $239000.0 in Q1 2025.